Price Forecast:

Bullish Case: QTRX's unique multi-marker diagnostic technologies offer high growth potential in Alzheimer's testing, supported by increasing demand for blood-based diagnostics and partnerships in key markets like China.

Bearish Case: Continued operational losses and fierce competition from larger companies could hinder QTRX's ability to capture market share, further impacting stock price negatively amid high implied volatility.

Potential Outcomes:

• Strong revenue growth driven by multi-marker test adoption (45%)
• Operational constraints continue, leading to stagnation (30%)
• Regulatory approval delays hinder growth prospects (15%)
• Increased competition impacts market positioning (10%)

Trading Oracle: Considering the implied volatility surface, a bullish debit spread on the QTRX 02/21/2025 15.00 Call could be optimal, given its high delta and potential upside. Simultaneously, sell the 17.50 Call to hedge against volatility. Monitor for potential earnings boosts near key pharmaceutical partnerships for maximum gains.

November 23, 2024